
Please try another search
Psyence Biomedical Ltd. engages in the development of botanical psilocybin-based psychedelic medicines. It also evaluates natural psilocybin for the treatment of adjustment disorder in patients with an incurable cancer diagnosis in a palliative care context. The company’s lead product candidate is PEX010, which is in Phase IIb clinical study, a capsule containing naturally sourced psilocybin for treatment of anxiety and depression, including associated ailments, such as post-traumatic stress disorder PTSD, stress, grief, and adjustment disorder in the context of palliative care. It has a partnership with iNGENu Pty Ltd to conduct a Phase IIb clinical trial of PEX010 in psilocybin-assisted psychotherapy for the treatment of AjD due to incurable cancer. The company is based in Toronto, Canada. Psyence Biomedical Ltd. operates as a subsidiary of Psyence Group Inc.
Name | Age | Since | Title |
---|---|---|---|
Marc Gregory Balkin | 50 | 2024 | Independent Director |
Christopher Michael Bull | 55 | 2024 | Independent Director |
Jody Aufrichtig | 50 | 2024 | Co-Founder, Executive Chairman & Strategic Business Development Officer |
Neil Maresky | 59 | 2023 | CEO & Director |
Clive Ward Able | - | 2025 | Member of Scientific Advisory Board |
Albert P. Garcia-Romeu | - | 2025 | Chairman of Scientific Advisory Board |
Seth Feuerstein | 52 | 2024 | Member of Scientific Advisory Board & Independent Director |
Dan J. Stein | - | 2025 | Member of Scientific Advisory Board |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review